Publications by authors named "S Serrati"

Introduction: The treatment of glioblastoma is hindered by the blood-brain barrier (BBB) and rapid drug clearance by the immune system. To address these challenges, we propose a novel drug delivery system using liposomes modified with cell membrane fragments. These modified liposomes can evade the immune system, cross the BBB, and accumulate in tumor tissue through homotypic targeting, thereby delivering drugs like paclitaxel and carboplatin more effectively.

View Article and Find Full Text PDF

Small-cell lung cancer (SCLC) cases represent approximately 15% of all lung cancer cases, remaining a recalcitrant malignancy with poor survival and few treatment options. In the last few years, the addition of immunotherapy to chemotherapy improved clinical outcomes compared to chemotherapy alone, resulting in the current standard of care for SCLC. However, the advantage of immunotherapy only applies to a few SCLC patients, and predictive biomarkers selection are lacking for SCLC.

View Article and Find Full Text PDF
Article Synopsis
  • This study focuses on optimizing treatments for metastatic melanoma (MM) by developing cell membrane (CM)-modified nanoparticles (NPs) using microfluidics, which enhance drug delivery and targeting.
  • The researchers performed a direct membrane fusion process using synthetic liposomes and CM from MM cell lines, loading these hybrid liposomes with targeted agents like cobimetinib and lenvatinib.
  • Results showed that these hybrid liposomes had significantly better targeting and effectiveness against MM cells compared to standard liposomes or free drugs, while demonstrating low toxicity.
View Article and Find Full Text PDF

Background: Clinical drawback in checkpoint inhibitors immunotherapy (ICI) of metastatic melanoma (MM) is monitoring clinical benefit. Soluble forms of PD1(sPD1) and PD-L1(sPD-L1) and extracellular vesicles (EVs) expressing PD1 and PD-L1 have recently emerged as predictive biomarkers of response. As factors released in the blood, EVs and soluble forms could be relevant in monitoring treatment efficacy and adaptive resistance to ICI.

View Article and Find Full Text PDF

Immune checkpoints are involved in controlling the activation or inhibition of the immune response and are associated with receptors on the immune cell surface [...

View Article and Find Full Text PDF